A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
NCT00048204 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 372
Last updated 2017-10-09
Summary
A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
Conditions
- Depressive Disorder, Major
Interventions
- DRUG
-
GW597599B
- DRUG
-
paroxetine
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-11-04
- Primary Completion
- 2003-09-30
- Completion
- 2003-09-30
More Related Trials
-
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
NCT00629551 ·Status: COMPLETED ·Phase: PHASE3
-
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
NCT00057239 ·Status: COMPLETED ·Phase: PHASE2
-
An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
NCT00057226 ·Status: COMPLETED ·Phase: PHASE2
-
A Local Register Study For Major Depression Of Paroxetine Controlled Release
NCT00368303 ·Status: COMPLETED ·Phase: PHASE3
-
Duloxetine Versus Paroxetine for Major Depression
NCT00489775 ·Status: COMPLETED ·Phase: PHASE3
-
A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
NCT00073203 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of GW856553X For the Treatment of Depression
NCT00569062 ·Status: TERMINATED ·Phase: PHASE2
-
A Trial of AXS-05 in Patients With Major Depressive Disorder
NCT04019704 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
NCT03559192 ·Status: COMPLETED ·Phase: PHASE2
-
Depression Study In Elderly Patients
NCT00067444 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
NCT00880048 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235 ·Status: COMPLETED ·Phase: PHASE2
-
Study of NSI-189 for Major Depressive Disorder
NCT02695472 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Of New Medicine (GSK 372475) For The Treatment Of Depression
NCT00448058 ·Status: COMPLETED ·Phase: PHASE2
-
Major Depressive Disorder Study In Adults
NCT00049972 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
NCT06796868 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
NCT06309277 ·Status: COMPLETED ·Phase: PHASE2
-
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
NCT00463242 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
NCT00839176 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety, Efficacy and Tolerability Study of SEP-225289
NCT00584974 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
NCT03374475 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00411242 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
NCT02498392 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Desvenlafaxine in Treating Major Depressive Disorder.
NCT04364997 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
NCT00880399 ·Status: TERMINATED ·Phase: PHASE2